BRIEF-Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis
April 24, 2017 at 07:15 AM EDT
* Lilly announces phase 3 monarch 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis
